Ocugen Inc (OCGN)
$0.31 0.01 (1.72%)
10:02 EST OCGN Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 1.33M
Day's Range 0.30 - 0.31
52-Week Range 0.17 - 0.96
Dividend & Yield N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
- From InvestorPlace
- From the Web
Probably because it's not a buzzworthy coronavirus stock, you might not hear much about OCGN stock but it still has strong upside potential.
Ocugen continues to conduct at-the-market offerings to raise capital. But with a distant payoff, OCGN stock offers too much risk and not enough reward.
Because of the pandemic, OCGN stock attracts speculative interest. But it is not likely to pay off in the long-run
OCGN stock isn't the next great biotech play, but savvy traders can limit its risk.
Because of the dynamics of the new normal, troubled names like OCGN stock continue to attract speculative interest. Perhaps some math will finally dissuade these gamblers?
While Ocugen is unprofitable and in bad need of cash, OCGN stock could soar if its eye disease therapies see clinical success.
Ocugen is raising cash through its orphan drug designation, but it still faces risks. Make sure you treat OCGN stock as a speculation.
OCGN stock has held up despite the failure of what was its flagship drug. The remaining pipeline simply isn't strong enough for investors to risk more capital.
There's a good deal of downside risk, but Ocugen is worth a look. OCGN stock is likely to fall as Ocugen raises $30 million or 54% of its equity to fund operations over the next 2 plus years.
By Thomas Niel
Recent news helps the odds for OCGN stock, but speculators have gotten carried away. Don't waste your time (or risk your capital) with this.
Ocugen has no revenue and is years away from developing a product. While the cause of developing therapies to fight blindness is laudable, there's no money to be made with OCGN stock.
Ocugen got good news Aug. 14 announcing a fourth orphan drug designation for its ophthalmology gene therapy. OCGN stock is still a longshot.
OCGN stock has been a hot penny stock. But no revenue and a lead candidate that is years away, are reminders that Ocugen is still a penny stock.
Some red-hot penny stocks are worth chasing; OCGN stock is not one of them. In fact, this rally is worth fading.
The FDA just gave a special designation to one of Ocugen's flagship products. That is good for science and it's great for OCGN stock.
Initially, the stupendous rise of OCGN stock may give you the case of the FOMOs. But don’t let that emotions guide you as Ocugen is driven by completely irrational actors.
Ocugen got a crucial piece of good news from the FDA. But with the company's lead drug years from approval, OCGN stock remains speculative.
Ocugen just doesn't have the qualities that make it attractive to me. Particularly under a buck, OCGN stock is one to avoid.
Navellier RatingsPowered by Portfolio Grader